Subjects ” General neurology
HealthDay News – Moderna’s double-dose COVID-19 vaccine continues to offer strong protection against the new coronavirus six months after the second shot, the company reported Tuesday.
The late-stage follow-up results showed that six months after the second dose, the vaccine remained 90 percent effective against all cases of COVID-19 and 95 percent effective against severe cases of the disease, the Washington Post reported.
Moderna also said it is testing vaccine candidates that target certain variants of the new coronavirus, including the B.1.351 variant, which was first detected in South Africa. Some studies have shown that the variant can escape immunity from current vaccines. One of the candidates combines the vaccine against the B.1.351 variant with the original Moderna shot, which the company claims “offers the broadest level of immunity” when tested on mice.
The company announced that its first results on vaccines targeting specific variants will be submitted for peer publication, The Post reported.
The Washington Post article
COVID19 General Infectious Disease General Neurology
Would you like to read more?
Please log in or register first to view this content.
Next post in General Neurology